Cytori Cell Research Institute, Inc. (3750) AI Stock Analysis

• Market Cap: ¥7.50B
• Dividend Yield: N/A
• Average Volume (3M): 5.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.42
• Revenue Growth: -93.79%
• EPS Growth: -1332.86%
• Country: JP
• Employees: 10
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -22.51
• Shares Outstanding: 8,929,419
• 10 Day Avg. Volume: 2,510
• 30 Day Avg. Volume: 5,903
• PEG Ratio: <0.01
• Price to Book (P/B): 11.36
• Price to Sales (P/S): 58.59
• P/FCF Ratio: -7.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: ¥876.00 ▲(7.09% Upside)

Cytori Cell Research Institute's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, high leverage, and cash flow challenges. The technical analysis provides some positive signals but is overshadowed by the financial instability. The valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively result in a low overall stock score.

Positive Factors

Proprietary Technology

Cytori's proprietary technology in regenerative medicine provides a competitive edge, allowing it to offer unique cell-based therapies that can drive long-term growth and market differentiation.

Strategic Partnerships

Strategic partnerships with research institutions and healthcare providers enhance Cytori's market presence and product offerings, potentially leading to increased revenue and innovation in the long term.

Industry Position

Operating in the growing field of regenerative medicine, Cytori is well-positioned to capitalize on increasing demand for innovative medical treatments, supporting sustainable business growth.

Negative Factors

Revenue Decline

A significant decline in revenue growth indicates challenges in maintaining sales momentum, which could impact long-term financial stability and necessitates a strategic overhaul to reverse the trend.

High Financial Leverage

High financial leverage increases risk, especially in volatile industries like biotechnology, potentially limiting Cytori's ability to invest in growth and innovation due to increased debt servicing obligations.

Negative Cash Flow

Negative cash flow from operations indicates that Cytori's core business activities are not generating sufficient cash, posing liquidity challenges and necessitating improved cash management and operational efficiency.

Cytori Cell Research Institute, Inc. Business Overview & Revenue Model

Company Description

Cytori Cell Research Institute, Inc. is a biotechnology company specializing in regenerative medicine and cell therapy. The company focuses on developing innovative solutions for tissue repair and regeneration, leveraging its proprietary technologies that utilize adipose-derived stem cells. Cytori operates primarily within the healthcare sector, aiming to address unmet medical needs, particularly in areas such as cardiovascular diseases, orthopedic injuries, and wound healing.

How the Company Makes Money

Cytori generates revenue through a combination of product sales, research grants, and strategic partnerships. Its core revenue streams include the commercialization of its cell therapy products and related medical devices, which are marketed to hospitals and clinics. Moreover, the company often engages in collaborative research agreements with pharmaceutical firms and academic institutions, which provide funding and shared resources for development. Significant partnerships can enhance Cytori's research capabilities and expand its market reach, thereby contributing to its overall earnings.

Cytori Cell Research Institute, Inc. Financial Statement Overview

Summary

Cytori Cell Research Institute is facing significant financial headwinds. The income statement shows declining revenues and increasing losses, the balance sheet reveals high leverage and financial risk, and cash flow challenges are evident with negative operational cash flow and decreasing free cash flow. These factors contribute to a low financial performance score.

Income Statement

Cytori Cell Research Institute's income statement reveals significant challenges, as evidenced by declining revenue and profitability. The revenue has decreased considerably from previous years, and the gross profit has turned negative, indicating increased cost pressures. The net profit margin and EBIT margin are both negative, reflecting persistent losses. The revenue growth rate has been negative for the latest period, showing a decline in sales. These factors contribute to a low score, highlighting the need for revenue stabilization and cost management strategies.

Balance Sheet

The balance sheet indicates a precarious financial position with high leverage. The debt-to-equity ratio is substantial, suggesting heavy reliance on debt financing, which poses a risk given the industry volatility. However, despite the challenges, a moderate equity ratio shows that the company retains some level of equity relative to its assets. The return on equity is negative due to losses incurred, further emphasizing financial instability. Overall, the balance sheet reflects high financial risk, warranting cautious management.

Cash Flow

The cash flow statement presents concerning trends. The operating cash flow is negative, indicating core operations are not generating cash, and free cash flow has also decreased, showing challenges in maintaining liquidity. The free cash flow growth rate is negative, further exacerbating the liquidity concerns. The ratio of operating cash flow to net income is unfavorable, reflecting operational inefficiencies. These cash flow issues highlight the need for improved cash management and operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	88.37M	122.20M	1.56B	2.14B	1.34B	1.39B
Gross Profit	-32.93M	-55.56M	1.29B	1.27B	859.23M	760.32M
EBITDA	-1.49B	-2.02B	-603.09M	-705.34M	348.90M	-261.86M
Net Income	-1.83B	-2.14B	138.16M	-1.06B	-77.63M	-831.86M
Balance Sheet
Total Assets	735.36M	3.54B	5.82B	14.09B	16.01B	14.92B
Cash, Cash Equivalents and Short-Term Investments	369.76M	255.98M	1.04B	1.12B	851.56M	1.07B
Total Debt	0.00	2.65B	2.47B	8.51B	9.27B	8.53B
Total Liabilities	246.54M	2.91B	3.02B	11.43B	12.29B	11.38B
Stockholders Equity	488.81M	630.54M	2.79B	2.65B	3.71B	3.55B
Cash Flow
Free Cash Flow	0.00	-995.12M	-1.17B	-198.04M	-367.83M	-98.86M
Operating Cash Flow	0.00	-987.04M	-1.15B	-39.52M	-187.78M	-82.90M
Investing Cash Flow	0.00	22.90M	8.69B	-283.06M	-216.19M	6.70M
Financing Cash Flow	0.00	171.65M	-7.17B	294.23M	35.80M	150.65M

Cytori Cell Research Institute, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 818.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3750, the sentiment is Negative. The current price of 818 is below the 20-day moving average (MA) of 831.90, below the 50-day MA of 851.48, and below the 200-day MA of 831.45, indicating a bearish trend. The MACD of -9.80 indicates Negative momentum. The RSI at 39.23 is Neutral, neither overbought nor oversold. The STOCH value of 34.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3750.

Cytori Cell Research Institute, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4884	54 Neutral	¥3.00B	―	―	―	-9.77%	-13.81%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
3750	45 Neutral	¥7.50B	-4.10	―	―	-93.79%	-1332.86%
4564	42 Neutral	€8.13B	-7.95	-63.25%	―	99.87%	40.60%
4576	41 Neutral	¥5.48B	―	-86.84%	―	-9.39%	24.12%
4591	37 Underperform	¥4.28B	―	―	―	-100.00%	7.60%
4598	28 Underperform	¥6.59B	―	―	―	―	25.25%